Pieris Pharmaceuticals (NASDAQ: PIRS) has recently received a number of price target changes and ratings updates:. 1/27/2020 – Pieris Pharmaceuticals had its price target raised by analysts at HC Wainwright from $7.00 to $9.00. They now have a “buy” rating on the stock. Updating Our Thesis On Philip Morris International Inc ... Jan 29, 2020 · Citigroup downgraded the Philip Morris International Inc. (NYSE:PM) stock from Buy to Neutral. The rating was come-out on December 02, 2019. In another research note published on October 01, 2019 by BofA/Merrill, upgraded the stock from Neutral to Buy and gave a price target of $96 to PM stock. Pieris Pharmaceuticals (NASDAQ:PIRS) Shares Up 16.7% ...
5 days ago · Investment analysts at Robert W. Baird published a research note on March 13, 2020 where it informed investors and clients that Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) is now rated as Outperform. Their price target on the stock stands at $5.
Pieris Pharmaceuticals - PIRS - Stock Price & News | The ... Real time Pieris Pharmaceuticals (PIRS) stock price quote, stock graph, news & analysis. Real time Pieris Pharmaceuticals (PIRS) stock price quote, stock graph, news & analysis. TipRanks View the overall analyst consensus for any stock, as well as the average analyst consensus price target for any stock. Average Price Target $ 9.00 (328.57% upside) Currently not enough data available to determine average price target. (PIRS) downgraded to Neutral from Outperform at Baird. 30 July, 2019.
Upgrades galore for NASDAQ:PIRS lately as analysts see great upside potential for the company. Most recently PIRS presented data from a phase 1 study on its new technology ANTICALIN which it is developing in collaboration with NYSE:AZN was released and commented on …
View the real-time PIRS price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying Current, Vs Industry, Vs History. 3-Year Average Share Buyback Ratio, -5.5. Valuation & Return. Current, Vs Industry, Vs History. Price-to-Tangible-Book, 2.65 . PIRS | Pieris Pharmaceuticals Inc. Analyst Estimates ... Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's PIRS Price Target and Analyst Ratings (Pieris Pharmaceuticals) Oct 27, 2019 · Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 234.93%. The high price target for PIRS is $9.00 and the low price target for PIRS is $5.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Based on analysts offering 12 month price targets for PIR in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .
Pieris Pharmaceuticals (NASDAQ:PIRS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Friday, Zacks.com reports. The firm currently has a $2.50 target price on the biotechnology company’s stock. Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Down 1.1% ... A decline of 95% from the average daily volume of 466,779 shares. The stock had previously closed at $3.67. Several research analysts have recently issued reports on PIRS shares. HC Wainwright raised their price objective on Pieris Pharmaceuticals from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Pieris Pharmaceuticals Inc. - NASDAQ:PIRS - Stock Quote ... Mar 27, 2020 · View detailed financial information, real-time news, videos, quotes and analysis on Pieris Pharmaceuticals Inc. (NASDAQ:PIRS). Explore commentary on … Pieris stock: buy or sell? - PIRS
Stock analysis for Pieris Pharmaceuticals Inc (PIRS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company
Is It Right Time to Be Bullish on Pieris Pharmaceuticals ... 13 hours ago · That day the Robert W. Baird set price target on the stock to $5. The stock was given Buy rating by Jefferies in its report released on March 19, 2018, the day when the price target on the stock was placed at 12. Evercore ISI was of a view that PIRS is … Is It Right Time to Be Cautious on Merit Medical Systems ... 5 days ago · Investment analysts at Robert W. Baird published a research note on March 13, 2020 where it informed investors and clients that Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) is now rated as Outperform. Their price target on the stock stands at $5.